<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343125">
  <stage>Registered</stage>
  <submitdate>28/06/2011</submitdate>
  <approvaldate>29/06/2011</approvaldate>
  <actrnumber>ACTRN12611000660987</actrnumber>
  <trial_identification>
    <studytitle>Using d-cycloserine to increase the effects of exposure for children's general fears</studytitle>
    <scientifictitle>d-cycloserine vs placebo combined with in-vivo exposure in the reduction of specific fears among children with broad-based anxiety disorders</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Child anxiety</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>d-cycloserine - 50 mg oral capsules, taken on 5 weekly occasions, approximately 60 minutes prior to each initial exposure
in-vivo exposure - 5 weekly sessions of approximately 30 minutes with a therapist. Exposure is conducted hierarchically during sessions to main identified fear.</interventions>
    <comparator>placebo - oral microcellulose capsule taken as above - ie 5 indiviaul doses at weekly sessions approximately 60 minutes prior to initial exposure.
All participants (including those on placebo) receive identical in-vivo exposure.</comparator>
    <control>Placebo</control>
    <interventioncode>Behaviour</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anxiety and avoidance of key fear assessed via behavioural avoidance test</outcome>
      <timepoint>Pre, Weekly for 5 weeks, post</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>General anxiousness assessed via Spence Children's Anxiety Scale</outcome>
      <timepoint>Pre, Weekly for 5 weeks, post</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DSM diagnosis of anxiety disorder
Availability of specific fear</inclusivecriteria>
    <inclusiveminage>7</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>14</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Psychotic experiences
Suicidal risk
Kidney disease
Liver disease
Epilepsy
Prior allergic reaction to antibiotics</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants are diagnosed and assessed by clinician who is independent of study. All those who meet criteria are invited to participate. Group allocation (active vs placebo) done by random number generator. Allocation and blind is held by hosptial pharmacist who is not involved in study in any other way. Therapist, interviewers, and participants are all blind to condition.</concealment>
    <sequence>Random number generator.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/09/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Macquarie University</primarysponsorname>
    <primarysponsoraddress>Balaclava Rd
North Ryde.
NSW. 2109</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Research Council</fundingname>
      <fundingaddress>Level 2, 11 Lancaster Place
 Majura Park ACT 2609</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial aims to test the efficacy of d-cycloserine (DCS) to augment the effects of in-vivo exposure for children's fears. It is hypothesised that anxious children who receive in-vivo exposure for a specific fear will show reductions in that fear and that use of DCS will increase the rate and extent of fear reduction. Children will receive 5 individual sessions of graduated exposure for a key, specific fear and will take either DCS (50 mg) or placebo approx 60 minutes before exposure.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Macquarie University Human Research Ethics Committee</ethicname>
      <ethicaddress>Balaclava Rd.
North Ryde.
NSW. 2109.</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>6/07/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Ronald Rapee</name>
      <address>Department of Psychology,
Macquarie University,
Sydney. NSW. 2109</address>
      <phone>61 2 98508032</phone>
      <fax>61 2 98508062</fax>
      <email>Ron.Rapee@mq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Ronald Rapee</name>
      <address>Department of Psychology,
Macquarie University,
Sydney. NSW. 2109.</address>
      <phone>61 2 98508032</phone>
      <fax>61 2 98508062</fax>
      <email>Ron.Rapee@mq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Ronald Rapee</name>
      <address>Department of Psychology,
Macquarie University,
Sydney. NSW. 2109</address>
      <phone>61 2 98508032</phone>
      <fax>61 2 98508062</fax>
      <email>Ron.Rapee@mq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>